AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt
A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused and the FDA imposed a clinical hold. NEW YORK, Oct. 8, 2026 /PRNewswire/ -- SueWallSt tracks...
Covered in this story
What has happened since
- Aardvark Therapeutics Inc is down 17.2% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AARD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aardvark Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.